iRadimed (NASDAQ:IRMD) Issues Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Q1 beat and raised guidance: iRadimed reported non‑GAAP EPS of $0.49 and revenue of $21.98M, topping estimates, and updated FY2026 EPS guidance to $2.06–$2.21 with Q2 guidance of $0.44–$0.48 while announcing a quarterly dividend of $0.20.
• FDA clearance of the MRidium 3870: Management says the cleared pump carries ~12% higher ASP and could unlock large replacement demand from >6,200 U.S. channels, targeting an eventual domestic pump revenue lift toward ~$50M in 2026, though rollout will be controlled through year‑end.
• Near‑term headwinds: International sales slipped (‑9%), a facility move and remaining capex may pressure free cash flow and operating expenses, and Q2 revenue guidance is modestly cautious versus the street despite backlog support.

iRadimed (NASDAQ:IRMD - Get Free Report) issued its earnings results on Friday. The medical equipment provider reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.46 by $0.03, FiscalAI reports. The company had revenue of $21.98 million for the quarter, compared to analysts' expectations of $21.32 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed updated its FY 2026 guidance to 2.060-2.210 EPS and its Q2 2026 guidance to 0.440-0.480 EPS.

Here are the key takeaways from iRadimed's conference call:

• Record quarter and raised guidance: Q2 revenue was $20.4M (+14% YoY) with 78% gross margin and GAAP diluted EPS of $0.45 (+18% YoY); management raised FY2025 revenue guidance to $80.0–$82.5M, raised EPS ranges, and declared a $0.17 quarterly dividend.
• FDA clearance of the MRidium 3870: Management calls the clearance a "seminal" event and expects the new pump (≈12% higher ASP) to unlock large replacement demand from >6,200 U.S. 5+-year-old channels, targeting an eventual domestic pump device revenue lift toward ~$50M in 2026.
• Backlog and commercial cadence: The company reports a record backlog (pump backlog ~5–6 months, monitor backlog ~4–5 weeks) and plans a controlled rollout—limiting broad selling of the 3870 through year‑end—so pump bookings may be muted initially even while revenue is supported by backlog.
• Near-term headwinds and international softness: International revenue declined 9% (domestic now ~89% of sales), the facility move will cause short-lived operational inefficiencies, and ongoing capex (final facility payments) could pressure near-term free cash flow and operating expenses.

iRadimed Trading Up 4.4%

Shares of IRMD stock traded up $3.71 during mid-day trading on Friday, reaching $87.15. The stock had a trading volume of 346,336 shares, compared to its average volume of 103,465. The stock's 50-day moving average price is $96.69 and its two-hundred day moving average price is $93.87. iRadimed has a 52-week low of $50.31 and a 52-week high of $107.90. The firm has a market capitalization of $1.11 billion, a PE ratio of 49.80 and a beta of 1.11.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a $0.20 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's payout ratio is presently 45.71%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Lake Street Capital reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital upgraded shares of iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. Finally, Roth Mkm reiterated a "buy" rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $120.00.

Insider Activity

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $101.38, for a total value of $506,900.00. Following the transaction, the chief executive officer owned 2,242,500 shares in the company, valued at approximately $227,344,650. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 48,750 shares of company stock valued at $4,708,950 in the last 90 days. 36.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after acquiring an additional 234 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of iRadimed by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,782 shares of the medical equipment provider's stock valued at $466,000 after buying an additional 458 shares during the period. Tower Research Capital LLC TRC increased its position in shares of iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 495 shares during the period. Swiss National Bank increased its position in shares of iRadimed by 3.2% during the fourth quarter. Swiss National Bank now owns 16,300 shares of the medical equipment provider's stock valued at $1,586,000 after buying an additional 500 shares during the period. Finally, Quarry LP purchased a new position in shares of iRadimed during the third quarter valued at about $40,000. Hedge funds and other institutional investors own 92.34% of the company's stock.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.